Fig. 1. Age-dependent distribution of AKI risk factors

Slides:

Advertisements

Similar presentations

Figure 1 Alcohol consumption. A

Advertisements

Fig. 4. Carer ratings of executive functioning (Dysexecutive Questionnaire) and memory (Memory Checklist) in the 3 groups at the beginning and end of the.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

FIGURE 4: Mean change from baseline in iPTH concentration during treatment and 60 days after treatment withdrawal. Data are shown as the mean change ±

Fig. 1. Significant clusters in the amygdala and dlPFC, four-way interaction effect (group by valence by temperature by time), small volume corrected.

From: Dynamic De/Centralization in Canada, 1867–2010

Figure 3: (a and b) Preoperative contrast-eCT

Figure 1. Unified models predicting gene regulation based on landscapes of gene-regulating factors. For each gene, position specific combinatorial patterns.

Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.

Figure 2. Number of cases required in a Mendelian randomization analysis with a binary outcome and a single instrumental variable for 80% power with a.

J Exp Bot. 2017;68(17): doi: /jxb/erx352

Figure 2. Chronic kidney disease risk tool application.

Fig. 1. Scheme for classifying renal function without access to laboratory test results. *Renal-specific drugs: phosphate binders (ATC codes.

Fig 1 The CONSORT participant flow diagram for primary endpoints.

Figure 1. An example of an original simulation film used during the 1960s to 1990s to plan radiotherapy for Hodgkin lymphoma, with field borders marked.

Figure 1 Study flow chart.

Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.

From: Learning by Working in Big Cities

Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.

From: THE FALLACIES OF PATENT-HOLDUP THEORY

Fig. 1. Trial structure for the experimental task.

Fig. 1 Nodes in a conceptual knowledge graph

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

From: Nutrition and brain development in early life

From: Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant In vitro Susceptibilities: Risk factors and Taxon-level.

From: Detection of Bacteriuria by Canine Olfaction

Figure 1: (A, frontal) and (B, lateral) Final result, 4 months post-operative, after right breast reconstruction using combined TRAM flap and LDMF. From:

Figure 2. Temperature-entropy diagram and the flow resistances of the power plant model of Figure 1. From: Thermodynamic optimization of a triple-shaft.

Fig. 1 No. 17 Trinidad trap baited with hamster in swamp forest in Tennessee. (Online figure in color.) From: Use of Hamster-Baited No. 17 Trinidad Mosquito.

Fig. 1. RUbioSeq pipelines for exome variant detection and BS-Seq analyses. Dark gray boxes correspond to the main steps of the pipelines. Light gray boxes.

Figure 3: Full-body skeletal scintigraphy.

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Source:Zimnisky (2014). From: An Autopsy of Cooperation: Diamond Dealers and the Limits of Trust-Based Exchange Journal of Legal Analysis. Published online.

From: Herpes Zoster and Recurrent Herpes Zoster

Figure 1. Study population diagram

Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

ADAb: anti-drug antibody.

FIGURE 1 Kidney biopsies of Patients 1 and 2

Figure 1 Hazard ratios as a function of annual mean PM2

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Flow chart of patient enrollment and exclusion

Figure 1 The occurrence of maternal cardiovascular events for the different diagnosis groups. AOP, aortic pathology; ... Figure 1 The occurrence of maternal.

Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.

Fig. 1 Mean change from baseline in ANC ± s. e

Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.

Figure 1. (A) Ab+ patients showed significantly more often a cognitive impairment compared with ab− patients [57.1% ... Figure 1. (A) Ab+ patients showed.

FIGURE 1 Participant flow diagram. Exercise Counseling Clinic (ECC).

Graph 1. The number of homicide cases per year discussing neuro-evidence. Unless provided in the caption above, the following copyright applies to the.

Figure 1. Analysis of human TRIM5α protein with Blast-Search and PhyML+SMS ‘One click’ workflow. (A) NGPhylogeny.fr ... Figure 1. Analysis of human TRIM5α.

Figure 2. Natural history of chlamydia transmission, with arrows showing the transitions between health states. Figure 2. Natural history of chlamydia.

Figure 1 Nelson-Aalen estimates of the cumulative incidence rates for patients on versus off IST. ON = optic neuritis; ... Figure 1 Nelson-Aalen estimates.

FIGURE 1 Study consort diagram

Fig. 2 Case 2. Levels of serum creatinine and anti-GBM antibodies before and during treatment with cyclophosphamide, ... Fig. 2 Case 2. Levels of serum.

Figure 1 Study flowchart and patient flow

Figure 1. Schematic diagram of solar energy and coal-fired power generation system. Unless provided in the caption above, the following copyright applies.

Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. ... Figure 1. Time to clinical stability.

Figure 1. The framework of NetGO with seven steps

Figure 1 Patient disposition

Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and.

Figure 1. Trial profile. (A) Part A and (B) part B

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Figure 1 Genetic results. No case had more than one diagnostic result

Figure 1. (A) Baseline contrast-enhanced CT scan of melanoma patient presenting with metastases in the liver and lymph ... Figure 1. (A) Baseline contrast-enhanced.

Figure 1 Mechanisms of mitral regurgitation.

Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening.

Presentation transcript:

Fig. 1. Age-dependent distribution of AKI risk factors Fig. 1. Age-dependent distribution of AKI risk factors. (A) The average number of AKI risk factors by indicated age groups with the error bars representing the standard deviation. (B) The percentage of patients in each age group with no risk factors and (C) the percentage of the total patient cohort within each age group. From: Acute kidney injury risk assessment at the hospital front door: what is the best measure of risk? Clin Kidney J. 2015;8(6):673-680. doi:10.1093/ckj/sfv080 Clin Kidney J | © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Fig. 2. (A) Age-dependent distribution of patients at high risk of AKI Fig. 2. (A) Age-dependent distribution of patients at high risk of AKI. High risk of AKI was defined as the presence of two or more fixed patient-related AKI risk factors. (B) Individual AKI risk factor (AKI-R) distribution. (B) Percentage of patients (solid black bars), patients ≥65 years of age (grey bars) or patients <65 years of age (open bars), positive for each of the individual fixed patient-related AKI risk factors. DM, diabetes mellitus; CKD, chronic kidney disease; BP, hypertension; IHD, ischaemic heart disease; CCF, congestive cardiac failure; CVD, cerebrovascular disease; PVD, peripheral vascular disease; Ob, morbid obesity; LD, liver disease; Neuro, neurological or cognitive impairment; AIDS, known diagnosis of AIDS; ACEi, angiotensin converting enzyme inhibitor; D, prescription of diuretic; NSAID, prescription of non-steroidal anti-inflammatory drugs). From: Acute kidney injury risk assessment at the hospital front door: what is the best measure of risk? Clin Kidney J. 2015;8(6):673-680. doi:10.1093/ckj/sfv080 Clin Kidney J | © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Fig. 3. Distribution of AKI risk factors (AKI-R) in HA- (solid bars) and CA-AKI (open bars). The data are expressed as a percentage of patients from either cohort. For significance, the appropriate P-value is shown. For each risk factor when no P-value is listed, the differences were not statistically significant. From: Acute kidney injury risk assessment at the hospital front door: what is the best measure of risk? Clin Kidney J. 2015;8(6):673-680. doi:10.1093/ckj/sfv080 Clin Kidney J | © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Fig. 4. Receiver operator characteristic curve for AKI prediction score for the whole cohort of patients using the AKI risk factors excluding age (A) or age alone (B), compared with the HA-AKI cohort using the AKI risk factors excluding age (C) or age alone (D) and the CA-AKI cohort using the AKI risk factors excluding age (E) or age alone (F). Solid line: prediction score, dashed line, reference line. From: Acute kidney injury risk assessment at the hospital front door: what is the best measure of risk? Clin Kidney J. 2015;8(6):673-680. doi:10.1093/ckj/sfv080 Clin Kidney J | © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com